Detailed answers about STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED, including incorporation, status, business activity, and accounts information.
When was STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED founded?
STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED was officially incorporated on 25 September 2014 and is registered under company number 09234622. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED?
STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED do?
STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED operates in the following sector: 74909 - Other professional, scientific and technical activities n.e.c.. This provides insight into the company's primary business activity and industry focus.
What is STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED's registered address?
The registered office address of STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED is OAKMERE, BELMONT BUSINESS PARK, DURHAM, ENGLAND, DH1 1TW. This is the official address filed with Companies House for legal and statutory correspondence.
Is STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED financially stable?
The most recent accounts for STRATEGIC PRE-CLINICAL PRODUCT DEVELOPMENT LIMITED were made up to 30 September 2024, filed as UNAUDITED ABRIDGED. Next accounts are due by 30 June 2026.